Investigates patient outcomes and adverse events related to cannabis use in MS, indicating potential benefits.
To investigate changes in health-related patient-reported outcome measures (PROMs) and adverse events in patients prescribed cannabis-based medicinal products (CBMPs) for multiple sclerosis (MS).
No takes yet. Share an insight, caveat, or question.
Shah et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: